"Genes, p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
| Descriptor ID |
D016158
|
| MeSH Number(s) |
G05.360.340.024.340.375.249.385 G05.360.340.024.340.415.400.385
|
| Concept/Terms |
Genes, p53- Genes, p53
- TP53 Genes
- Genes, TP53
- Gene, TP53
- TP53 Gene
- p53 Genes
- Gene, p53
- p53 Gene
|
Below are MeSH descriptors whose meaning is more general than "Genes, p53".
Below are MeSH descriptors whose meaning is more specific than "Genes, p53".
This graph shows the total number of publications written about "Genes, p53" by people in this website by year, and whether "Genes, p53" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 26 | 11 | 37 |
| 1995 | 31 | 10 | 41 |
| 1996 | 23 | 6 | 29 |
| 1997 | 21 | 7 | 28 |
| 1998 | 30 | 12 | 42 |
| 1999 | 19 | 15 | 34 |
| 2000 | 23 | 13 | 36 |
| 2001 | 16 | 14 | 30 |
| 2002 | 23 | 13 | 36 |
| 2003 | 17 | 19 | 36 |
| 2004 | 12 | 10 | 22 |
| 2005 | 12 | 17 | 29 |
| 2006 | 13 | 12 | 25 |
| 2007 | 9 | 5 | 14 |
| 2008 | 7 | 8 | 15 |
| 2009 | 8 | 10 | 18 |
| 2010 | 10 | 10 | 20 |
| 2011 | 15 | 9 | 24 |
| 2012 | 3 | 9 | 12 |
| 2013 | 4 | 6 | 10 |
| 2014 | 4 | 4 | 8 |
| 2015 | 5 | 2 | 7 |
| 2016 | 5 | 3 | 8 |
| 2017 | 3 | 7 | 10 |
| 2018 | 1 | 5 | 6 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 4 | 5 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 2 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genes, p53" by people in Profiles.
-
Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data. J Clin Oncol. 2024 Jun 20; 42(18):2186-2195.
-
DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors. Cancer Res Commun. 2023 10 16; 3(10):2096-2112.
-
Triple-negative breast tumors are dependent on mutant p53 for growth and survival. Proc Natl Acad Sci U S A. 2023 08 22; 120(34):e2308807120.
-
Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. Am J Hematol. 2023 08; 98(8):1176-1184.
-
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst. 2022 12 08; 114(12):1619-1627.
-
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022 10 20; 140(16):1753-1763.
-
Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma. Commun Biol. 2022 07 28; 5(1):757.
-
Local Anti-PD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model. Cancer Prev Res (Phila). 2021 08; 14(8):767-778.
-
Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Cancer Discov. 2021 08; 11(8):2094-2111.
-
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. Cancer. 2021 08 01; 127(15):2666-2673.